Curemark Celebrates World Autism Awareness Day as a Visionary Sponsor of Several Autism Speaks 2016 Walks

Share Article

Curemark Partners with Autism Advocacy Organization to Support Efforts in Raising Awareness and Funds for Autism

Curemark, a drug research and development company focused on the treatment of neurological diseases for unmet medical needs, announced today that it has partnered with Autism Speaks, the world’s leading autism science and advocacy organization, on a multi-regional level to support the Autism Speaks Walk program. Curemark will kick off its participation on April 2nd, Autism Awareness Day, at the Los Angeles Walk in Pasadena, California.

“At Curemark, we are focused on autism and supporting the children and families impacted by this disorder,” says Dr. Joan Fallon, founder and CEO of Curemark. “We are proud to partner with Autism Speaks to aid in their incredible efforts to raise awareness around autism.”

The Autism Speaks Los Angeles Walk is one of 62 around the country. In addition to participating in the walk on April 2nd, Curemark is a Visionary Sponsor in other cities as well. Curemark will support walks in California, Texas, Ohio, New York, and Connecticut as well as in other locations throughout the U.S. To learn more about Autism Speaks Walk program visit http://www.autismspeakswalk.org.

About Curemark
Curemark, LLC is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of neurological disorders. Curemark’s pipeline includes preclinical and clinical-stage programs for the treatment of Autism, ADHD, addiction, Schizophrenia and Parkinson’s disease. For additional information, please visit http://www.curemark.com or follow @curemark on Twitter.

About CM-AT
CM-AT, Curemark’s lead drug candidate, has been granted “Fast Track” designation by the U.S. Food and Drug Administration for the investigation of Autism. The company is currently enrolling a Phase III double blind, randomized, placebo-controlled clinical trial (known as the Blüm Study) to examine the effect of CM-AT in children ages 3-8 with Autism. The trial is enrolling in over 20 sites across the United States. For additional information, please see: http://www.blumstudy.com.

About Autism
Autism is a general term used to describe a group of complex developmental brain disorders – autism spectrum disorders – caused by a combination of genes and environmental influences. These disorders are characterized, in varying degrees, by communication difficulties, social and behavioral challenges, and repetitive behaviors.

About Autism Speaks
Autism Speaks is the world’s leading autism science and advocacy organization. It is dedicated to funding research into the causes, prevention, treatments and a cure for autism; increasing awareness of autism spectrum disorders; and advocating for the needs of individuals with autism and their families. Autism Speaks was founded in February 2005 by Suzanne and Bob Wright, the grandparents of a child with autism. Since its inception, Autism Speaks has committed more than $570 million to its mission, the majority in science and medical research. On the global front, Autism Speaks has established partnerships in more than 70 countries on five continents to foster international research, services and awareness. To learn more about Autism Speaks, please visit AutismSpeaks.org.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Shay Pantano
Rubenstein PR
+1 212-805-3062
Email >
Visit website